Table 1.
Patient characteristics
| Clinical characteristics | At diagnosis (n = 22) | Follow-up (n = 60) | Patient total | Controls | |||||
|---|---|---|---|---|---|---|---|---|---|
| CP | AP | BP | CHR | CP | AP | BP | |||
| Patients, n | 20 | 0 | 2 | 52 | 1 | 1 | 6 | 82 | 32 |
| Male/female | 12/8 | 0/0 | 0/2 | 41/11 | 0/1 | 0/1 | 6/0 | 59/23 | 12/20 |
| Age, year median (range) |
54 (22–74) |
– |
60 (53, 66) |
50 (11–82) |
82 | 68 |
44 (19–68) |
47 (11–82) |
54 (17–80) |
| TKI therapy | |||||||||
| Imatinib | – | – | – | 40 | 0 | 1 | 0 | 41 | – |
| Dasatinib | – | – | – | 5 | 0 | 0 | 3 | 8 | – |
| Nilotinib | – | – | – | 5 | 1 | 0 | 3 | 9 | – |
| Radotinib | – | – | – | 2 | 0 | 0 | 0 | 2 | – |
| Lymphocyte subset, median (% of cells) | |||||||||
| CD3+ T-cell | 71.4 | – | 78.3 | 65.8 | 49.2 | 60.6 | 80.4 | 67.3 | 67.7 |
| CD3+ CD4+ T-cell | 29.5 | – | 34.7 | 26.8 | 24.1 | 35.3 | 29.8 | 28.2 | 27.2 |
| CD3+ CD8+ T-cell | 35.3 | – | 40.1 | 31.6 | 10.9 | 20.6 | 38.5 | 33.4 | 33.3 |
| CD4/CD8 ratio | 0.86 | – | 0.95 | 0.87 | 2.21 | 1.71 | 0.76 | 0.86 | 0.84 |
CP chronic phase, AP accelerated phase, BP blast phase, CHR complete hematologic response, TKI tyrosine kinase inhibitor